Please assess the completion status of the following clinical trial:

Trial Title: Ipratropium Bromide in Peri-Operative COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* All patients must sign an informed consent.~* Male or female patients aged \>= 40 years and \<= 80 years~* All patients must be diagnosed with COPD and must meet the following spirometric criterion: post-bronchodilator forced expiratory volume in 1 second (FEV1) \< 70% of forced vital capacity (FVC) at Screening Visit (Visit 1).~* All patients have relatively stable COPD (i.e. have no COPD exacerbation within 4 weeks prior to Screening Visit).~* All patients are about to receive selective surgical procedures of lobectomy or right bilobectomy or segmentectomy under general anaesthesia, whilst the estimated time of surgical procedures lasts for not less than 2 hours, and the estimated time of general anaesthesia lasts for not less than 3 hours and not longer than 5 hours.~* Patients must be able to perform all study related procedures including technically acceptable pulmonary function tests (PFTs).~Exclusion criteria:~* Patients who need maintenance treatment of bronchodilators (including anticholinergics, ß-agonists, xanthines).~* Patients with a recent history (i.e. six months or less) of myocardial infarction~* Patients with any unstable or life-threatening cardiac arrhythmia requiring intervention or change in drug therapy during the last year~* Patients with symptomatic chronic heart failure (i.e. New York Heart Association functional class III-IV)~* Known narrow angle glaucoma~* Patients with prostatic hyperplasia or bladder neck obstruction with significant symptoms~* Patients with a history of asthma, allergic rhinitis or who have a blood eosinophil count \>= 600 / mm3 (0.6×10\^9/L). A repeat eosinophil count will not be conducted in these patients

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ipratropium (Type: EXPERIMENTAL): 500 mcg four times a day
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).